Clinic of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Hs C, 24105, Kiel, Germany.
Kurt-Semm-Center for Laparoscopic and Robot-Assisted Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.
J Robot Surg. 2022 Dec;16(6):1265-1271. doi: 10.1007/s11701-022-01390-0. Epub 2022 Mar 4.
In various disciplines, robotic-assisted surgery is a well-proven routine procedure, but have never been established in vascular surgery so far. This review summarizes the results to date of robotic-assisted abdominal aortic surgery (RAAS) in the treatment of aorto-iliac occlusive disease (AIOD) and abdominal aortic aneurysm (AAA). Web-based literature search of robotic-assisted surgical procedures on the abdominal aorta and iliac arteries between 1990 and 2020 including the Cochrane Library, OVID Medline, Embase, and PubMed medical databases. All studies conducting Robotic-assisted surgery were included in the quantitative analysis regarding operative and cross-clamping times, conversion rates, mortality and morbidity within the first 30 days, and in-hospital stay. Case reports and case studies (< 5 patients) were not included. Twenty-four studies were deemed thematically eligible for inclusion; after exclusion of duplicate publications, nine met the inclusion criteria for further analysis. A total of 850 patients who had either abdominal aortic aneurysm or aorto-iliac occlusive disease underwent RAAS. One study of abdominal aortic aneurysm, three of aorto-iliac occlusive disease, and five studies of both disease entities were analyzed quantitatively. For AAA, conversion rates ranged from 13.1 to 20% and perioperative mortality ranged from 0 to 1.6% with in-hospital stay of 7 days. For aorto-iliac occlusive disease, conversion rates ranged from 0 to 20%, and perioperative mortality ranged from 0 to 3.6% with in-hospital stay of 5-8 days. RAAS has been shown to be technically feasible with acceptable short-term outcomes and questionable benefits in terms of in-hospital stay and complication rates. RAAS is currently considered only an outsider procedure. Randomized-controlled trials are indispensable for regular use in vascular surgery as well as a clear approval situation for the vascular sector.
在各个学科领域,机器人辅助手术已经是一种经过充分验证的常规手术,但迄今为止尚未在血管外科领域得到应用。本文综述了机器人辅助腹主动脉手术(RAAS)在治疗主髂动脉闭塞性疾病(AIOD)和腹主动脉瘤(AAA)方面的最新研究结果。通过网络检索 1990 年至 2020 年间在 Cochrane 图书馆、OVID Medline、Embase 和 PubMed 医学数据库中关于机器人辅助腹主动脉和髂动脉手术的文献,所有开展机器人辅助手术的研究均纳入手术和阻断时间、中转率、30 天内死亡率和发病率以及住院时间的定量分析。未纳入病例报告和病例研究(<5 例)。24 项研究被认为主题上符合纳入标准,在排除重复发表的文献后,有 9 项符合进一步分析的纳入标准。共有 850 例患有腹主动脉瘤或主髂动脉闭塞性疾病的患者接受了 RAAS 治疗。对 1 项腹主动脉瘤研究、3 项主髂动脉闭塞性疾病研究和 5 项同时涉及这两种疾病的研究进行了定量分析。对于 AAA,中转率为 13.1%至 20%,围手术期死亡率为 0%至 1.6%,住院时间为 7 天。对于 AIOD,中转率为 0%至 20%,围手术期死亡率为 0%至 3.6%,住院时间为 5-8 天。RAAS 已被证明在技术上是可行的,具有可接受的短期结果,在住院时间和并发症发生率方面存在疑问。RAAS 目前仅被视为一种辅助手术。随机对照试验对于血管外科的常规应用以及血管领域的明确审批情况都是不可或缺的。